Successful completion of the first stage of the phase IIa clinical trial of naptumomab in combination with docetaxel and the study is now enrolling into the second stage
June 1, 2022
News
Active Biotech enters into global patent license agreement with Oncode Institute for tasquinimod in myelofibrosis
February 9, 2022
Active Biotech announces first patient dosed in the combination part of the phase Ib/IIa study of tasquinimod in multiple myeloma
February 7, 2022
First subject dosed in phase I clinical study with eye-drop formulation of laquinimod
December 10, 2021
Data on naptumomab estafenatox enhancing CAR-T cells potency presented by Active Biotech’s partner NeoTX at SITC 2021
November 24, 2021
Active Biotech’s partner NeoTX to Present at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 9, 2021
New preclinical data on tasquinimod will be presented at the annual meeting of American Society of Hematology (ASH)
November 4, 2021
Active Biotech’s partner NeoTX will host KOL webinar on overcoming check point Inhibitor resistance
July 8, 2021
Active Biotech’s presentation at “Aktiedagen” May 4, 2021 (Swedish shareholders’ association, in Swedish)
May 4, 2021
Active Biotech and NeoTX announce FDA Clearance of IND for Phase II Clinical Trial of Naptumomab
April 19, 2021
Active Biotech enters into a manufacturing agreement with Famar Health Care Services for new formulation of Laquinimod
February 4, 2021
Adjustment of period for trading in subscription rights and interim shares in Active Biotech’s rights issue
January 7, 2021